Breaking News
FONT-SIZE Plus   Neg
Share SHARE

CACI International Q2 Profit Rises; Lifts FY12 EPS Estimate - Quick Facts

RELATED NEWS
Trade CACI now with 

CACI International Inc. (CACI) reported second-quarter net income attributable to the company of $41.1 million or $1.51 per share, compared to $33.2 million or $1.08 per share in the prior year quarter.

Pro forma adjusted net income attributable to the company for the quarter rose to $54.4 million or $2.00 per share from $45.9 million or $1.48 per share in the comparable quarter last year.

On average, 16 analysts polled by Thomson Reuters expected earnings of $1.30 per share for the quarter. Analysts' estimates typically exclude one-time items.

Revenues for the quarter grew 12.2 percent to $973.24 million from $867.28 million last year, while fifteen analysts estimated revenues of $952.78 million for the quarter.

Looking forward to the fiscal year 2012, the company raised its earnings guidance range to $5.72 - $5.94 per share, from the prior estimate of $5.55 - $5.80 per share. Analysts currently estimate earnings of $5.67 per share for the full year.

The company expects its revenue guidance for the full year 2012 to the range of $3,850 million to $4,050 million, same as the prior estimate. Analysts currently estimate revenues of $3.92 billion for the full year.

Click here to receive FREE breaking news email alerts for CACI International Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Proctor and Gamble (PG) has sold two of its soap brands to European consumer products giant Unilever (UN). Cincinnati-based P&G says the sale includes the global Camay brand, the Zest brand outside of North America and its Talisman manufacturing plant in Mexico. The plant employs approximately... Dish Network is no longer carrying Fox News in yet another dispute for the television provider. Fox News, which changed the face of cable news with its ardent advocacy of conservative issues, went dark Sunday, replaced on Dish by The Blaze, Glen Beck's new right-leaning channel. Fox Business channel... Swiss drug maker Roche Holding said a late-stage trial of its breast cancer drug Kadcyla did not provide superior results compared with an existing therapy.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.